Share Price and Basic Stock Data
Last Updated: November 22, 2025, 2:59 pm
| PEG Ratio | 2.51 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Global Health Ltd operates within the Non-Banking Financial Company (NBFC) sector, with its stock price currently standing at ₹1,213 and a market capitalization of ₹32,596 Cr. The company’s revenue has demonstrated a robust upward trajectory, with sales rising from ₹2,167 Cr in FY 2022 to ₹3,275 Cr in FY 2024, and trailing twelve months (TTM) revenue reported at ₹4,005 Cr. Quarterly sales figures also reflect this growth, with the latest quarter ending June 2025 reporting sales of ₹1,031 Cr. This consistent increase in revenue indicates a strong market position and effective operational strategies. The company’s operating profit margin (OPM) has stabilized around 24%, suggesting efficient cost management. Given the current market dynamics, Global Health Ltd is well-positioned to capitalize on growth opportunities within the financial services landscape.
Profitability and Efficiency Metrics
In terms of profitability, Global Health Ltd has shown significant improvements, with net profits increasing from ₹196 Cr in FY 2022 to ₹481 Cr in FY 2025, contributing to a net profit margin of 13.03% for the same period. The company’s return on equity (ROE) stands at a commendable 16.5%, while return on capital employed (ROCE) is reported at 19.7%. These figures indicate effective utilization of shareholders’ equity and capital. However, the price-to-earnings (P/E) ratio of 54.5 suggests that the stock may be overvalued compared to its earnings, which could raise concerns for potential investors. The interest coverage ratio (ICR) at 14.65x implies a strong capacity to meet interest obligations, enhancing confidence in the company’s financial health. Overall, Global Health Ltd’s profitability metrics reflect strong operational efficiency, although the high valuation may warrant caution.
Balance Sheet Strength and Financial Ratios
Global Health Ltd’s balance sheet reflects a solid financial position, with no reported borrowings, which indicates a debt-free status and a conservative capital structure. The company’s current ratio of 2.48 and quick ratio of 2.37 suggest a robust liquidity position, allowing it to meet short-term obligations comfortably. The book value per share has risen to ₹126.08, showcasing growth in shareholder equity. Moreover, the total debt-to-equity ratio is reported at 0.09, indicating minimal leverage. However, the absence of reserves may pose a risk if unexpected financial challenges arise. The company’s asset turnover ratio of 0.81 demonstrates efficient use of assets to generate revenue, although it remains slightly below the sector average. Overall, the balance sheet metrics highlight a strong financial foundation, albeit with some concerns regarding reserve management.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Global Health Ltd illustrates a diverse ownership structure, with promoters holding 33.01% of the stake, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 11.41% and 12.97%, respectively. The public holds 42.56% of shares, reflecting solid retail investor interest. Over recent quarters, promoter holdings have seen a slight decline, which may raise questions about insider confidence. Conversely, FIIs have gradually increased their stake, rising from 9.36% in December 2022 to 11.36% by December 2023, indicating growing institutional interest. The number of shareholders has also increased to 1,55,806, highlighting a growing base of retail investors. This mix of institutional and retail ownership can enhance market stability and confidence in the company’s future prospects.
Outlook, Risks, and Final Insight
Looking ahead, Global Health Ltd is positioned to benefit from the expanding NBFC sector, supported by its strong revenue growth and profitability metrics. However, the high P/E ratio and the absence of reserves pose potential risks, as they could limit financial flexibility in challenging market conditions. Additionally, the declining promoter stake may raise concerns among retail investors regarding long-term commitment. Conversely, the increasing institutional interest signifies confidence in the company’s strategic direction and operational efficiency. To navigate these challenges, the company may need to focus on building reserves and maintaining clear communication with stakeholders. Overall, while Global Health Ltd has a solid foundation for growth, investors should remain vigilant regarding its financial strategies and market positioning in the evolving landscape of the financial services sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Global Health Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Minolta Finance Ltd | 13.3 Cr. | 1.33 | 1.91/0.93 | 1.07 | 0.00 % | 0.40 % | 0.09 % | 1.00 | |
| Money Masters Leasing & Finance Ltd | 10.8 Cr. | 1.08 | 11.4/1.03 | 31.9 | 1.57 | 0.00 % | 4.42 % | 3.94 % | 1.00 |
| Moneyboxx Finance Ltd | 450 Cr. | 138 | 269/130 | 80.1 | 0.00 % | 8.65 % | 0.58 % | 10.0 | |
| Moongipa Capital Finance Ltd | 14.2 Cr. | 15.4 | 37.9/15.0 | 10.6 | 26.6 | 0.00 % | 12.1 % | 9.43 % | 10.0 |
| Morarka Finance Ltd | 41.4 Cr. | 92.0 | 180/90.0 | 22.1 | 238 | 1.09 % | 2.46 % | 2.17 % | 10.0 |
| Industry Average | 28,817.59 Cr | 467.54 | 54.95 | 522.84 | 0.22% | 15.80% | 8.84% | 8.50 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 617 | 679 | 694 | 707 | 780 | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 |
| Expenses | 485 | 522 | 534 | 540 | 595 | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 |
| Operating Profit | 133 | 157 | 160 | 167 | 184 | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 |
| OPM % | 21% | 23% | 23% | 24% | 24% | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% |
| Other Income | 9 | 16 | 12 | 25 | 15 | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 |
| Interest | 19 | 18 | 21 | 20 | 18 | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 |
| Depreciation | 36 | 37 | 39 | 38 | 40 | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 |
| Profit before tax | 87 | 117 | 112 | 133 | 141 | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 |
| Tax % | 33% | 27% | 28% | 24% | 28% | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% |
| Net Profit | 59 | 86 | 81 | 101 | 102 | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 |
| EPS in Rs | 2.32 | 3.38 | 3.01 | 3.77 | 3.80 | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 |
Last Updated: August 19, 2025, 2:37 pm
Below is a detailed analysis of the quarterly data for Global Health Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,031.00 Cr.. The value appears strong and on an upward trend. It has increased from 931.00 Cr. (Mar 2025) to 1,031.00 Cr., marking an increase of 100.00 Cr..
- For Expenses, as of Jun 2025, the value is 784.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 707.00 Cr. (Mar 2025) to 784.00 Cr., marking an increase of 77.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 225.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 22.00 Cr..
- For OPM %, as of Jun 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00%.
- For Other Income, as of Jun 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from -27.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 47.00 Cr..
- For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 15.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 45.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 49.00 Cr. (Mar 2025) to 45.00 Cr., marking a decrease of 4.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 208.00 Cr.. The value appears strong and on an upward trend. It has increased from 133.00 Cr. (Mar 2025) to 208.00 Cr., marking an increase of 75.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00%.
- For Net Profit, as of Jun 2025, the value is 159.00 Cr.. The value appears strong and on an upward trend. It has increased from 101.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 58.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.92. The value appears strong and on an upward trend. It has increased from 3.78 (Mar 2025) to 5.92, marking an increase of 2.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:15 am
| Metric | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,005 |
| Expenses | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,049 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 956 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 24% |
| Other Income | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 29 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 62 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 193 |
| Profit before tax | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 730 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | |
| Net Profit | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 562 |
| EPS in Rs | 35.10 | 6.78 | 10.44 | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 | 17.92 | 20.91 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 54.55% | -29.41% | -19.44% | 575.86% | 66.33% | 46.63% | 0.63% |
| Change in YoY Net Profit Growth (%) | 0.00% | -83.96% | 9.97% | 595.31% | -509.54% | -19.70% | -46.00% |
Global Health Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 19% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 38% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 17% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 3:36 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 |
| ROCE % | 6% | 6% | 5% | 15% | 17% | 20% | 20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 10.00 |
| Basic EPS (Rs.) | 17.92 | 17.80 | 12.58 | 7.78 | 1.15 |
| Diluted EPS (Rs.) | 17.92 | 17.80 | 12.57 | 7.77 | 1.14 |
| Cash EPS (Rs.) | 25.13 | 24.24 | 17.75 | 12.87 | 30.66 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 126.08 | 108.21 | 90.54 | 63.82 | 272.22 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 126.08 | 108.21 | 90.54 | 63.82 | 272.22 |
| Revenue From Operations / Share (Rs.) | 137.47 | 121.98 | 100.46 | 85.56 | 291.76 |
| PBDIT / Share (Rs.) | 35.60 | 32.54 | 25.25 | 19.34 | 44.94 |
| PBIT / Share (Rs.) | 28.39 | 26.11 | 19.66 | 14.22 | 20.09 |
| PBT / Share (Rs.) | 24.10 | 23.36 | 16.75 | 11.08 | 6.55 |
| Net Profit / Share (Rs.) | 17.92 | 17.80 | 12.16 | 7.75 | 5.81 |
| NP After MI And SOA / Share (Rs.) | 17.92 | 17.81 | 12.16 | 7.75 | 5.81 |
| PBDIT Margin (%) | 25.89 | 26.67 | 25.13 | 22.60 | 15.40 |
| PBIT Margin (%) | 20.64 | 21.40 | 19.56 | 16.61 | 6.88 |
| PBT Margin (%) | 17.52 | 19.14 | 16.67 | 12.94 | 2.24 |
| Net Profit Margin (%) | 13.03 | 14.59 | 12.10 | 9.05 | 1.99 |
| NP After MI And SOA Margin (%) | 13.03 | 14.60 | 12.10 | 9.05 | 1.99 |
| Return on Networth / Equity (%) | 14.21 | 16.45 | 13.42 | 12.14 | 2.13 |
| Return on Capital Employeed (%) | 18.38 | 19.01 | 14.87 | 13.20 | 4.35 |
| Return On Assets (%) | 10.10 | 11.11 | 7.92 | 6.23 | 1.06 |
| Long Term Debt / Equity (X) | 0.07 | 0.09 | 0.30 | 0.47 | 0.42 |
| Total Debt / Equity (X) | 0.09 | 0.14 | 0.34 | 0.51 | 0.47 |
| Asset Turnover Ratio (%) | 0.81 | 0.77 | 0.61 | 0.69 | 0.52 |
| Current Ratio (X) | 2.48 | 2.44 | 2.76 | 1.94 | 1.24 |
| Quick Ratio (X) | 2.37 | 2.33 | 2.65 | 1.81 | 1.14 |
| Inventory Turnover Ratio (X) | 55.11 | 10.81 | 9.00 | 10.58 | 8.41 |
| Interest Coverage Ratio (X) | 14.65 | 11.82 | 8.69 | 6.16 | 3.32 |
| Interest Coverage Ratio (Post Tax) (X) | 9.14 | 7.47 | 5.18 | 3.47 | 1.43 |
| Enterprise Value (Cr.) | 31388.50 | 34786.03 | 13675.20 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 8.50 | 10.62 | 5.08 | 0.00 | 0.00 |
| EV / EBITDA (X) | 32.83 | 39.81 | 20.20 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 8.72 | 10.85 | 5.24 | 0.00 | 0.00 |
| Price / BV (X) | 9.50 | 12.23 | 5.81 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 8.72 | 10.85 | 5.24 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 |
After reviewing the key financial ratios for Global Health Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 17.92, marking an increase of 0.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 17.92, marking an increase of 0.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 25.13. This value is within the healthy range. It has increased from 24.24 (Mar 24) to 25.13, marking an increase of 0.89.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 126.08. It has increased from 108.21 (Mar 24) to 126.08, marking an increase of 17.87.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 126.08. It has increased from 108.21 (Mar 24) to 126.08, marking an increase of 17.87.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 137.47. It has increased from 121.98 (Mar 24) to 137.47, marking an increase of 15.49.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 35.60. This value is within the healthy range. It has increased from 32.54 (Mar 24) to 35.60, marking an increase of 3.06.
- For PBIT / Share (Rs.), as of Mar 25, the value is 28.39. This value is within the healthy range. It has increased from 26.11 (Mar 24) to 28.39, marking an increase of 2.28.
- For PBT / Share (Rs.), as of Mar 25, the value is 24.10. This value is within the healthy range. It has increased from 23.36 (Mar 24) to 24.10, marking an increase of 0.74.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 17.92, marking an increase of 0.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 17.81 (Mar 24) to 17.92, marking an increase of 0.11.
- For PBDIT Margin (%), as of Mar 25, the value is 25.89. This value is within the healthy range. It has decreased from 26.67 (Mar 24) to 25.89, marking a decrease of 0.78.
- For PBIT Margin (%), as of Mar 25, the value is 20.64. This value exceeds the healthy maximum of 20. It has decreased from 21.40 (Mar 24) to 20.64, marking a decrease of 0.76.
- For PBT Margin (%), as of Mar 25, the value is 17.52. This value is within the healthy range. It has decreased from 19.14 (Mar 24) to 17.52, marking a decrease of 1.62.
- For Net Profit Margin (%), as of Mar 25, the value is 13.03. This value exceeds the healthy maximum of 10. It has decreased from 14.59 (Mar 24) to 13.03, marking a decrease of 1.56.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.03. This value is within the healthy range. It has decreased from 14.60 (Mar 24) to 13.03, marking a decrease of 1.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.21. This value is below the healthy minimum of 15. It has decreased from 16.45 (Mar 24) to 14.21, marking a decrease of 2.24.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.38. This value is within the healthy range. It has decreased from 19.01 (Mar 24) to 18.38, marking a decrease of 0.63.
- For Return On Assets (%), as of Mar 25, the value is 10.10. This value is within the healthy range. It has decreased from 11.11 (Mar 24) to 10.10, marking a decrease of 1.01.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.07, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.14 (Mar 24) to 0.09, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has increased from 0.77 (Mar 24) to 0.81, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.48. This value is within the healthy range. It has increased from 2.44 (Mar 24) to 2.48, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 2.37. This value exceeds the healthy maximum of 2. It has increased from 2.33 (Mar 24) to 2.37, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 55.11. This value exceeds the healthy maximum of 8. It has increased from 10.81 (Mar 24) to 55.11, marking an increase of 44.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14.65. This value is within the healthy range. It has increased from 11.82 (Mar 24) to 14.65, marking an increase of 2.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.14. This value is within the healthy range. It has increased from 7.47 (Mar 24) to 9.14, marking an increase of 1.67.
- For Enterprise Value (Cr.), as of Mar 25, the value is 31,388.50. It has decreased from 34,786.03 (Mar 24) to 31,388.50, marking a decrease of 3,397.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.50. This value exceeds the healthy maximum of 3. It has decreased from 10.62 (Mar 24) to 8.50, marking a decrease of 2.12.
- For EV / EBITDA (X), as of Mar 25, the value is 32.83. This value exceeds the healthy maximum of 15. It has decreased from 39.81 (Mar 24) to 32.83, marking a decrease of 6.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.72. This value exceeds the healthy maximum of 3. It has decreased from 10.85 (Mar 24) to 8.72, marking a decrease of 2.13.
- For Price / BV (X), as of Mar 25, the value is 9.50. This value exceeds the healthy maximum of 3. It has decreased from 12.23 (Mar 24) to 9.50, marking a decrease of 2.73.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.72. This value exceeds the healthy maximum of 3. It has decreased from 10.85 (Mar 24) to 8.72, marking a decrease of 2.13.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Global Health Ltd:
- Net Profit Margin: 13.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.38% (Industry Average ROCE: 15.8%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.21% (Industry Average ROE: 8.84%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 55.2 (Industry average Stock P/E: 54.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Non-Banking Financial Company (NBFC) | Sir RNM House, Kolkata West Bengal 700001 | gcmil1995@gmail.com http://www.globalcapitalmarketandinfraltd.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Inder Chand Baid | Chairman & Managing Director |
| Mr. Mahavir Prasad Saraswat | Independent Director |
| Mr. Urmi Bose | Independent Director |
| Ms. Akshaya Suved Chavan | Independent Director |
| Mr. Manish Baid | Non Executive Director |